

1 **Sequence analysis of plasmid pSP02 from *Bifidobacterium longum* M62 and**
2 **construction of pSP02-derived cloning vectors**

3

4 Pablo Álvarez-Martín^{1,2‡}, Joanna Życka-Krzesińska^{1,2‡}, Jacek Bardowski², and Baltasar
5 Mayo^{1*}

6

7 Department of Microbiology and Biochemistry, Instituto de Productos Lácteos de
8 Asturias (IPLA-CSIC), Carretera de Infiesto, s/n, 33300-Villaviciosa, Asturias, Spain¹,
9 and Institute of Biochemistry and Biophysics of Polish Academy of Sciences,
10 Pawinskiego 5a, 02-106 Warszawa, Poland²

11

12 RUNNING TITLE: Analysis of a *Bifidobacterium longum* plasmid

13 KEYWORDS: *Bifidobacterium longum*, bifidobacteria, plasmid, cloning vectors,
14 probiotics

15

16 ‡These authors contributed equally to this work.

17 *Corresponding author: Baltasar Mayo, Departamento de Microbiología y Bioquímica
18 de Productos Lácteos, Instituto de Productos Lácteos de Asturias (IPLA-CSIC),
19 Carretera de Infiesto s/n, 33300 Villaviciosa, Asturias, Spain

20 Tel: +34 985 89 21 31

21 Fax: +34 985 89 22 33

22 e-mail: baltasar.mayo@ipla.csic.es

23

24 **Abstract**

25 Replicons from bifidobacteria species are required for the construction of general-
26 and special-purpose vectors that would allow the undertaking of molecular studies of
27 these bacteria. In this work, pSP02, a cryptic plasmid from *Bifidobacterium longum*
28 M62, was cloned, sequenced and characterized. pSP02 was found to consist of 4896 bp
29 with four ORFs coding for proteins over 50 amino acids long. Among the deduced
30 protein sequences only a replicase (RepA) and a mobilization-like protein (MobA)
31 showed known functional domains. Similar to previously described bifidobacterial
32 plasmids, the organization of the putative *ori* region of pSP02 resembles that of the
33 theta-replicating plasmids of Gram-positives. In spite of this, hybridization experiments
34 detected single stranded (ss)-DNA as an intermediate product in the pSP02 replication,
35 demonstrating it follows the rolling-circle (RC) replication mode. The *ori* region of
36 pSP02 was used to construct a series of first generation cloning vectors able to replicate
37 in many bifidobacterial species. Real time quantitative PCR established the copy
38 number of pSP02 and its derived vectors to be around 12 copies per chromosome
39 equivalent. pSP02-derivatives showed full segregational and structural stability even in
40 the absence of antibiotic selection.

41

42

43 **Introduction**

44 *Bifidobacterium* species are among the dominant microbial populations of the
45 gastrointestinal tract (GIT) of humans and other mammals, where they are considered to
46 be responsible for a vast array of effects beneficial to health, including the production of
47 short chain fatty acids, the exclusion of intestinal pathogens, and the modulation of
48 immune function (Russell et al., 2011). These beneficial activities have led to the

49 extensive use of selected bifidobacterial strains as probiotics. However, the basic
50 mechanisms by which bifidobacteria contribute to well-being remain poorly understood.
51 This knowledge is extremely important for the long-term exploitation of bifidobacterial
52 probiotics as promoters of health (Russell et al., 2011; Siciliano and Mazzeo, 2012).

53 The molecular study of bifidobacterial properties has traditionally been hampered by
54 a lack of genetic tools (Ventura et al., 2004). Bifidobacteria have recently been
55 envisioned as promising systems for the delivery of therapeutic agents such as antigens
56 (for live vaccine development) and tumor-suppressing substances (Fujimori, 2006; Xu
57 et al., 2007), but for this, stable and robust expression vectors are also needed. The lack
58 of molecular tools further impedes the full exploitation of the genetic data provided by
59 the recent genome sequencing of many bifidobacterial strains
60 (http://www.ncbi.nlm.nih.gov/sutils/genom_table.cgi). Since bacteriophages infecting
61 *Bifidobacterium* species have never been characterized, and only a few prophage-like
62 element have been identified in the bifidobacterial genomes (Ventura et al., 2005),
63 plasmids would seem to be the only feasible type of replicon that can be used to
64 construct these needed vectors.

65 To date over 40 plasmid sequences have been reported to the GenBank database
66 (<http://www.ncbi.nlm.nih.gov/nucleotide>), and a few plasmid replicons have been studied
67 in detail (O’Riordan and Fitzgerald, 1999; Park et al., 1999; Corneau et al, 2004; Lee
68 and O’Sullivan, 2006; Park et al., 2008). Some of these have already been used to
69 construct general cloning and expression vectors (Matsumara et al., 1997; Yazawa et al.,
70 2001; Klijn et al., 2006; Rhim et al., 2006; Takata et al., 2006; Cronin et al., 2007;
71 Álvarez-Martín et al., 2008), and some special-purpose vectors, such as
72 bioluminescence reporter systems (Cronin et al., 2008; Guglielmetti et al., 2008).

73 However, more plasmids are still needed to develop compatible vector systems and
74 construct food grade vectors and gene integration, disruption and replacement cassettes.

75 This work reports the molecular analysis of pSP02, a cryptic plasmid from
76 *Bifidobacterium longum* M62. This replicon was used to construct first generation
77 cloning vectors able to replicate stably in different bifidobacterial species and strains,
78 including some used as commercial probiotics.

79

80

81 **Material and Methods**

82

83 **Bacterial strains, cloning vectors and growth conditions**

84 Table 1 shows the bacterial strains and vectors used in this study. Bifidobacteria
85 strains were grown in anaerobiosis at 37°C in MRS broth (Merck, Darmstad, Germany)
86 or RCM broth (Merck) supplemented with 0.25% (w/v) L-cysteine (Sigma-Aldrich, St.
87 Louis, MO, USA). *Escherichia coli* was grown with shaking at 37°C in Luria Bertani
88 (LB) broth (Sambrook and Russell, 2001). When required, antibiotics (all from Sigma-
89 Aldrich) were added at the following concentrations: ampicillin 100 µg ml⁻¹ and
90 tetracycline 5 µg ml⁻¹ for *E. coli* and erythromycin 5 µg ml⁻¹ and tetracycline 5 µg ml⁻¹
91 for bifidobacteria.

92

93 **Isolation of plasmid DNA**

94 Plasmid DNA from bifidobacteria was isolated using the method of O'Sullivan and
95 Klaenhamer (1993) with the modification that pellets were suspended in TSE buffer
96 (sucrose 25%, 50 mM Tris-HCl, 10 mM EDTA, pH 8.0) and incubated with lysozyme
97 (30 mg/ml) at 37°C for 30 min. Plasmid DNA from *E. coli* was isolated using the

98 commercial QIAprep® Spin Miniprep kit (Qiagen GmbH, Hilden, Germany), following
99 the manufacturer's recommendations. Plasmids were analyzed by electrophoresis in
100 TAE (40 mM Tris-HCl, 40 mM acetic acid, and 1 mM EDTA, pH 8.0), visualized under
101 UV light and photographed.

102

103 **Molecular DNA techniques**

104 The general procedures followed for DNA manipulation were essentially those
105 described by Sambrook and Russell (2001). Restriction endonucleases (Takara, Otsu,
106 Shiga, Japan), Taq DNA polymerase (Ampliqon A/S, SkovlundeDenmark), the Klenow
107 fragment of *E. coli* polymerase I and nuclease S1 (Roche Applied Sciences, Basel,
108 Switzerland), and T₄ DNA ligase (Invitrogen, Carlsbad, CA; USA) were used according
109 to the suppliers' instructions.

110 Cloning vectors and constructs were introduced into *E. coli* by electrotransformation
111 (electroporation) using a Gene-Pulser Apparatus (Bio-Rad Laboratories, Richmond,
112 CA, USA) according to Sambrook and Russell (2001). Electroporation of
113 *Bifidobacterium* cells was performed under the following conditions: 25 μF, 200 Ω and
114 10 kV (Álvarez-Martín et al., 2007). Transformants were recovered on selective RCM
115 agar plates incubated for 2-3 days at 37°C under anaerobic conditions.

116

117 **Sequencing and DNA sequence analysis**

118 The complete pSP02 sequence was obtained by sequencing cloned plasmid *Bam*HI
119 fragments into pUC18. In addition, the sequence of some segments was further verified
120 by PCR amplification and sequencing of the amplicons. DNA and deduced protein
121 sequences were examined for homology against non-redundant DNA and protein
122 databases using the on-line BLAST program (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>).

123

124 **DNA hybridization**

125 Plasmid DNA was transferred to Hybond-N nylon membranes (GE Health Care Bio-
126 Sciences, Little Chalfont, UK) after electrophoresis and hybridized, using as a probe a
127 digoxigenin-labeled internal segment of the *repA* gene obtained by PCR, under high-
128 stringency standard conditions (hybridization at 68°C and two final washing steps in 0.5
129 x SSC, 0.1% SDS at 68°C for 15 min) (Sambrook and Russell, 2001).

130 For the detection of ssDNA, whole-cell lysates from *B. pseudocatenuatum* M115
131 harboring pSP1 were obtained and purified as described by Leenhouts et al. (1991).
132 Unmodified DNA and DNA treated with nuclease S1 were then electrophoresed and
133 transferred to a hybridization membrane under non-denaturing conditions. ssDNA was
134 revealed by hybridization using the same *repA*-derived probe and labeling conditions as
135 above.

136

137 **Determination of the relative plasmid copy number**

138 The relative copy number of pSP02 and its derived vectors was assessed by
139 quantitative real-time PCR (qPCR) in a Fast Real-Time PCR system (Applied
140 Biosystems, Foster City, CA, USA) using Power SYBER® Green PCR Master Mix
141 (Applied Biosystems), and employing the PCR conditions reported by Álvarez-Martín
142 et al. (2008). Amplification of a segment of 139 bp was performed using two primers -
143 CopyF and CopyR (Table 1)- based on the pSP02 *repA* sequence. A 148 bp segment of
144 the single-copy Tu elongation factor gene of *B. longum* NCC2705 (*tuf*; GeneID:
145 1022637) was used as a reference. The relative copy number was calculated from
146 triplicate experiments using the formula $N_{\text{relative}} = (1+E)^{-\Delta CT}$ (Lee et al., 2006), where E is

147 the amplification efficiency of the target and reference genes, and Δ CT the difference
148 between the threshold cycle number (CT) of the *tuf* reaction and that of *repA*.

149

150 **Segregation and structural stability of vectors**

151 The stability of the constructs was assayed in *B. pseudocatenulatum* M115 by
152 growing the cells in non-selective RCM-cysteine medium for approximately 100
153 generations and plating daily onto antibiotic-free agar plates. Plasmid segregation was
154 monitored by transference of the colonies to plates with and without antibiotics. Finally,
155 structural stability was monitored in representative resistant and susceptible colonies by
156 plasmid isolation and restriction analysis.

157

158 **Nucleotide sequence accession number**

159 The nucleotide and deduced amino acid sequences of pSP02 are available under
160 GenBank accession no. GU256055.

161

162

163 **Results and Discussion**

164

165 **Cloning and sequencing of pSP02**

166 The plasmid complement of *B. longum* M62 has been shown to be composed of three
167 plasmids of lengths around 3.5 (pSP01), 5.0 (pSP02) and 14.0 (pSP03) kbp (Álvarez-
168 Martín et al., 2007). Restriction analysis of the whole plasmid complement of strain
169 M62 showed pSP02 to be digested by *Bam*HI into two fragments of approximately 2.35
170 and 2.65 kbp; neither pSP01 nor pSP03 were cut with this enzyme. The digestion
171 fragments were ligated into *Bam*HI-digested pUC18, and the ligation mixture

172 electroporated into *E. coli* DH11S. Plasmid DNA from each of the clones was isolated,
173 purified and sequenced. To check the sequence around the *Bam*HI positions, primers
174 were designed to amplify segments flanking the *Bam*HI sites (Table 1). Sequencing of
175 the amplicons confirmed that the whole molecule of pSP02 was composed of only these
176 two *Bam*HI fragments, and to be 4896 bp long. The single *Kpn*I restriction enzyme site
177 was used as a starting point for numbering nucleotides in a clockwise direction with
178 respect to the ORF encoding the putative replicase RepA (Fig. 1). The GC content of
179 the plasmid molecule was shown to be 62%, slightly higher than that recorded for the *B.*
180 *longum* chromosome (60%) (Schell et al., 2002). It also showed a nucleotide sequence
181 almost identical to that of other bifidobacterial plasmids, such as p6043A from *B.*
182 *longum* DPC6043 (DQ458910), pB80 from *Bifidobacterium bifidum* B80 (DQ305402;
183 Shokoporov et al., 2008), or pBIFA24 from *Bifidobacterium* spp. A24 (DQ286581).
184 Less -but still extensive- homology was shown with the sequence of plasmids pKJ50
185 (BLU76614; Park et al., 1999), p157F-NC2 (AP010891) and pNAL8M (AM183144;
186 Guglielmetti et al., 2007), and others. Furthermore, hybridization experiments using as a
187 probe the whole *repA* gene amplified with primers RepAF and RepAR (Table 1)
188 showed a replicon closely related to pSP02 to be present in certain plasmid-containing
189 strains of our collection (data not shown). Thus, a plasmid identical or very similar to
190 pSP02 seems to be well spread among *B. longum* strains, and is also present in other
191 bifidobacterial species (Shkoporov et al., 2008). As these plasmids are all cryptic, the
192 biological significance of the presence of pSP02-type replicons is at present unknown. It
193 may represent a very successful replicon in bifidobacteria, as is the case of WO02-type
194 plasmids in *Lactococcus lactis* (Seegers et al., 1994).

195

196 **Sequence analysis of pSP02**

197 Four ORFs coding for proteins over 50 amino acids long were predicted into the
198 pSP02 molecule (Fig. 1). Among the deduced proteins only a replicase (RepA) and a
199 mobilization-like protein (MobA) showed any known functional domain. RepA was
200 shown to consist of 303 amino acids long harboring a conserved replicase domain of the
201 Rep_3 protein superfamily (pfam01051). BLAST analysis showed RepA to differ from
202 the equivalent sequence of plasmid pB80 of *B. bifidum* B80 (Shkoporov et al., 2008) by
203 a single amino acid, and by two amino acids with respect to pNAL8M (Guglielmetti et
204 al., 2007). All these plasmids can be included in the phylogenetic group Ia of the
205 bifidobacterial plasmids (Guglielmetti et al., 2007). The deduced MobA protein of
206 pSP02 is thought to be composed of 370 amino acids. The protein contained a
207 conserved domain of transfer relaxases of the MobA_MobL superfamily (pfam03389).
208 The deduced amino acid sequence of two additional ORFs, *orf1* and *orf2*, showed no
209 putative conserved domains and share no homology to proteins in the databases.

210 A large number of direct (DR) and inverted (IR) repeats were detected in the pSP02
211 sequence. The approximate position of all these are indicated in Fig. 1. Secondary
212 structures of DRs and IRs were particularly abundant between *orf2* and *repA* genes.
213 These secondary structures conform what it is supposed to be the origin of replication
214 (*ori*) of pSP02, a region which is detailed in Fig. 2. In fact, the organization of this
215 region resembles that found in the *ori* region of plasmids of Gram-positive bacteria in
216 which the theta mode of replication has been experimentally demonstrated (Kiewiet et
217 al., 1993; del Solar et al., 1998). Two AT-rich stretches of 30 and 27 nt were identified
218 in this region, which are flanked by a typical DR of 22 nt (DR-6), repeated three times
219 and featuring an iteron structure similar to that in pKJ50 (Park et al., 1997). The first
220 and third repeats are identical and embrace an imperfect repeat in the middle (DR-6*)

221 (Fig. 2). Also noteworthy in the pSP02 sequence is the presence of a long IR of 38 nt,
222 the two copies of which are separated by more than 900 bps (IR-2 in Fig. 1).

223 No canonical *oriT*-like sequence was identified in front of *mobA*. However, a short
224 inverted repeat of eight nt (5'-ATGTTACC-GGT-GGTAACAT-3') separated by six bp
225 from a 12 nt sequence (5'-TAAGTGCGCCCT-3') resembling that present in some
226 mobilizable plasmids from Gram-positive bacteria (Lee and O'Sullivan, 2006), was
227 found through positions 3086 to 3050, 228 bp upstream of the start codon of *mobA*.

228

229 **Construction of pSP02-derived vectors**

230 Fig. 3 shows the general outline for the construction of the pSP02-derivatives. A
231 clone in pUC18 carrying the *Bam*HI fragment encoding *repA* was digested with *Bam*HI
232 and ligated into *Bam*HI-digested pUC19E, a pUC-derived vector unable to replicate in
233 bifidobacteria but harboring the erythromycin resistance gene of pE194 from
234 *Staphylococcus aureus*. The ligation mixture was electroporated into electrocompetent
235 *Bifidobacterium pseudocatenulatum* M115 cells. Transformants carrying the pSP02
236 fragment in the two opposite orientations were found, showing that orientation was not
237 essential for replication. It was also shown that neither *mobA* nor *orf1* nor the IRs
238 present in the other half of the molecule was necessary for replication.

239 One construct carrying the replicase in the same relative orientation to that of the
240 betalactamase gene in pUC19E, named pSP1 (Fig. 3), was selected and further
241 modified. As shown in the figure, the erythromycin resistance gene in pSP1 was
242 replaced by a bifidobacterial *tet(W)* gene encoding resistance to tetracycline (Álvarez-
243 Martín et al., 2008), giving rise to pSP2 (Fig. 3). This construct was first obtained in *E.*
244 *coli* and then transformed into *B. pseudocatenulatum*.

245 Finally, pSP1 was double digested with *EcoRI* and *HindIII*, treated with the Klenow
246 fragment of *E. coli* DNA polymerase I, re-ligated and transformed into the M115 strain.
247 Transformants lacking DNA from the pUC vector were recovered, thus demonstrating
248 that the replication of this construct, called pSP3 (Fig. 3), was driven by sequences and
249 elements from the pSP02 segment.

250

251 **Host range, copy number and stability of pSP02 derivatives**

252 A series of bifidobacterial strains belonging to different species, including
253 recognized probiotic strains such as *Bifidobacterium animalis* subsp. *lactis* Bb12 and
254 *Bifidobacterium breve* UCC 2003 (Table 2), were made competent and transformed
255 with one µg of DNA from all pSP02-derived constructs (pSP1, pSP2, and pSP3).
256 Though the transformation frequency varied widely among the different constructs and
257 strains, transformants were recovered in all cases, except for pSP3, for which, as
258 expected, transformants in *E. coli* were not obtained. As a general trend, pSP1 and pSP3
259 showed similar transformation frequencies in the different hosts, while fewer
260 transformants were usually obtained for pSP2. Transformants were obtained at low
261 frequency for pSP1 and pSP3 in a single strain of *Corynebacterium glutamicum*, which
262 belongs to the same phylum as bifidobacteria (*Actinobacteria*). However, no
263 transformants with pSP02-derivatives were recovered in several lactic acid bacterial
264 strains (Table 2), suggesting the replicon is not functional in this bacterial group.

265 The relative copy number per chromosome equivalent of pSP02 was analyzed in its
266 original host *B. longum* M62 by qPCR; those of the constructs were analyzed after
267 transformation into the plasmid-free strain *B. longum* L25. The standard amplification
268 curves both *repA* and *tuf* genes were linear over the tested range in both strains (average
269 R² >0.993). Assuming maximum and identical amplification efficiencies for the target

270 (*repA*) and reference (*tuf*) genes, the relative copy numbers per chromosome equivalent
271 of pSP02 was estimated to be around 12 copies in both strains (11.83±0.64 in *B. longum*
272 L25 and 12.39±0.92 in *B. longum* M62). A similar copy number was also established
273 under the same experimental conditions for all pSP02-derivatives in *B. longum* L25.
274 Copy number of pSP02 showed to be intermediate to that of pBC1 (30 copies per cell)
275 (Álvarez-Martín et al., 2007) and pCIBAO89 (4 copies per cell) (Cronin et al., 2007).

276 pSP1, pSP2, and pSP3 were checked for stability under non-selective conditions in
277 *B. pseudocatenuatum* M115. After 100 generations more than 80% of the colonies
278 retained each of the constructs. Plasmid analysis by digestion with restriction enzymes
279 showed that antibiotic resistant colonies contained the constructs without appreciable
280 structural changes.

281 pSP1 was also electroporated into strain M115 containing pAM4, a cloning vector
282 based on pBC1 from *B. catenuatum* L48 (Álvarez-Martín et al., 2008). The two
283 plasmids remained compatible and were stably maintained at similar frequencies to
284 those shown by each of the construct in this host.

285

286 **Mode of replication of pSP02**

287 As *B. longum* M62 carries three plasmids, to investigate the mode of replication of
288 pSP02, total DNA was isolated from an overnight culture of *B. longum* L25 harboring
289 vector pSP1. Purified untreated DNA and DNA treated with nuclease S1 were
290 transferred to a membrane under non-denaturing conditions and hybridized with the
291 above referred *recA*-derived probe. As can be seen in Fig. 4, pretreatment of the DNA
292 with nuclease S1, resulted in the loss of a hybridization band which is thought to
293 correspond to ssDNA. The detection of ssDNA as an intermediate in the replication of a
294 plasmid is currently used as a proof of using the RC type of replication (del Solar et al.,

295 1998; Khan, 1997). The apparent discrepancy between the physical organization of the
296 *ori* region of pSP02 (similar to theta-replicating plasmids) and the replication
297 proceeding by the RC mode has previously been noted for other *B. longum* plasmids
298 such as pKJ50 (Park et al., 1999) and pDOJH10L-RepB (Lee and O'Sullivan, 2006).

299 In conclusion, a cryptic plasmid from *B. longum* was analyzed and used for the
300 construction of cloning vectors that replicate in different bifidobacterial species.
301 Although presenting an iteron-like structure and other elements typical of theta-
302 replicating plasmids (AT-rich regions separated by GC-rich stretches), pSP02 was
303 shown to replicate through ssDNA intermediates, consistent with an RC mode. pSP02-
304 derived constructs showed convenient stability and copy number. These new plasmid
305 vectors could complement the genetic tools already available for performing molecular
306 studies on bifidobacteria and their genetic manipulation.

307

308

309 **Acknowledgments**

310 This work was done in the frame of scientific bilateral cooperation between the
311 Consejo Superior Investigaciones Científicas (CSIC) and the Polish Academy of
312 Sciences (PAN). Funding was obtained from projects from the Spanish Ministry of
313 Science and Innovation (MICINN) (Ref. AGL2011-24300-ALI) and the Institute of
314 Biochemistry and Biophysics-PAN (IBB-PAN).

315

316

317 **References**

318 Álvarez-Martín, P., Flórez, A.B., Mayo, B., 2007. Screening for plasmids among human
319 bifidobacteria species: Sequencing and analysis of pBC1 from *Bifidobacterium*
320 *catenulatum* L48. *Plasmid* 57, 165-174.

321 Álvarez-Martín, P., Flórez, A., Margolles, A., del Solar, G., Mayo, B., 2008. Improved
322 cloning vectors for bifidobacteria, based on the *Bifidobacterium catenulatum* pBC1
323 replicon. *Appl. Environ. Microbiol.* 74, 4656-4665.

324 Argnani, A., Leer, R.J., van Luijk, N., Pouwels, P.H., 1996. A convenient and
325 reproducible method to genetically transform bacteria of the genus *Bifidobacterium*.
326 *Microbiology* 142, 109-114.

327 Corneau, N., Emond, E., LaPointe, G., 2004. Molecular characterization of three
328 plasmids from *Bifidobacterium longum*. *Plasmid* 51, 87-100.

329 Cronin, M., Knobel, M., O'Connell-Motherway, M., Fitzgerald, G.F., van Sinderen, D.,
330 2007. Molecular dissection of a bifidobacterial replicon. *Appl. Environ. Microbiol.*
331 73, 7858-7866.

332 Cronin, M., Sleator, R.D, Hill, C., Fitzgerald, G.F., van Sinderen, D., 2008.
333 Development of a luciferase-based reporter system to monitor *Bifidobacterium breve*
334 UCC2003 persistence in mice. *BMC Microbiol.* 8: 161.

335 del Solar, G., Giraldo, R., Ruiz-Echevarría, M.J., Espinosa, M., Díaz-Orejas, R., 1998.
336 Replication and control of circular bacterial plasmids. *Microbiol. Mol. Biol. Rev.* 62,
337 434-464.

338 Fujimori, M., 2006. Genetically engineered *Bifidobacterium* as a drug delivery system
339 for systemic therapy of metastatic breast cancer patients. *Breast Cancer* 13, 27-31.

340 Guglielmetti, S., Karp, M., Mora, D., Tamagnini, I., Parini, C., 2007. Molecular
341 characterization of *Bifidobacterium longum* biovar *longum* NAL8 plasmids and

342 construction of a novel replicon screening system. *Appl. Microbiol. Biotechnol.* 74,
343 1053-1061.

344 Guglielmetti, S., Ciranna, A., Mora, D., Parini, C., Karp, M., 2008. Construction,
345 characterization and exemplificative application of bioluminescent *Bifidobacterium*
346 *longum* biovar *longum*. *Int. J. Food Microbiol.* 124, 285-290.

347 Khan, S.A., 1997. Rolling-circle replication of bacterial plasmids. *Microbiol. Mol. Biol.*
348 *Rev.* 61, 442–455.

349 Kiewiet, R., Bron, S., de Jonge, K., Venema, G. and Seegers, J.F.M.L., 1993. Theta
350 replication of the lactococcal plasmid pWVO2. *Mol. Microbiol.* 10, 319-327.

351 Klijn, A., Moine, D., Delley, M., Mercenier, A., Arigoni, F., Pridmore, R.D., 2006.
352 Construction of a reporter vector for the analysis of *Bifidobacterium longum*
353 promoters. *Appl. Environ. Microbiol.* 72, 7401-7405.

354 Lee, C.L., Ow, D.S., Oh, S.K., 2006. Quantitative real-time polymerase chain reaction
355 for determination of plasmid copy number in bacteria. *J. Microbiol. Methods* 65,
356 258-267.

357 Lee, J.H., O’Sullivan, D.J., 2006. Sequence analysis of two cryptic plasmids from
358 *Bifidobacterium longum* DJO10A and construction of a shuttle cloning vector. *Appl.*
359 *Environ. Microbiol.* 72, 527-535.

360 Leenhouts, K.J., Toiner, B., Bron, S., Kok, J., Venema, G., Seegers, J.F.M.L., 1991.
361 Nucleotide sequence and characterization of the broad host range lactococcal plasmid
362 pWVO1. *Plasmid* 26, 55-66.

363 Matsumura, H., Takeuchi, A., Kano, Y., 1997. Construction of *Escherichia coli*-
364 *Bifidobacterium longum* shuttle vector transforming *B. longum* 105-A and 108-A.
365 *Biosci. Biotechnol. Biochem.* 61, 1211-1212.

366 Missich, R., Sgorbati, B., Leblanc, D.J., 1994. Transformation of *Bifidobacterium*
367 *longum* with pRM2, a constructed *Escherichia coli*-*B. longum* shuttle vector. Plasmid
368 32, 208-211.

369 O’Riordan, K., Fitzgerald, G.F., 1999. Molecular characterisation of a 5.75-kb cryptic
370 plasmid from *Bifidobacterium breve* NCFB 2258 and determination of mode of
371 replication. FEMS Microbiol. Lett. 174, 285-294.

372 O’Sullivan, D.J., Klaenhammer, T.R., 1993. Rapid mini-prep isolation of high-quality
373 plasmid DNA from *Lactococcus* and *Lactobacillus* spp. Appl. Environ. Microbiol.
374 59, 2730-2733.

375 Park, M.S., Shin, D.W., Lee, K.H., Ji, G.E., 1999. Sequence analysis of plasmid pKJ50
376 from *Bifidobacterium longum*. Microbiology 145, 585-592.

377 Park, Y.S., Kim, K.H., Park, J.H., Oh, I.K., Yoon, S.S., 2008. Isolation and molecular
378 characterization of a cryptic plasmid from *Bifidobacterium longum*. Biotechnol. Lett.
379 30, 145-151.

380 Rhim, S.L., Park, M.S., Ji, G.E., 2006. Expression and secretion of *Bifidobacterium*
381 *adolescentis* amylase by *Bifidobacterium longum*. Biotechnol. Lett. 23, 163-168.

382 Russell, D.A., Ross, R.P., Fitzgerald, G.F., Stanton, C., 2011. Metabolic activities and
383 probiotic potential of bifidobacteria. Int. J. Food Microbiol. 149, 88-105.

384 Sambrook, J., Russell, D.W., 2001. Molecular cloning: a laboratory manual, 3rd ed.
385 Cold Spring Harbor Laboratory Press, Cold Spring Harbor.

386 Sangrador-Vegas, A., Stanton, C., van Sinderen, D., Fitzgerald, G.F., Ross, R.P., 2007.
387 Characterization of plasmid pASV479 from *Bifidobacterium pseudolongum* subsp.
388 *globosum* and its use for expression vector construction. Plasmid 58, 140-147.

389 Schell, M.A., Karmirantzou, M., Snel, B., Vilanova, D., Berger, B., Pessi, G., Zwahlen,
390 M.C., Desiere, F., Bork, P. Delley, M., Pridmore, R.D., Arigoni, F., 2002. The

391 genome sequence of *Bifidobacterium longum* reflects its adaptation to the human
392 gastrointestinal tract. Proc. Natl. Acad. Sci. USA 99, 14422-14427.

393 Seegers, J.F., Bron, S., Franke, C.M., Venema, G., Kiewiet, R., 1994. The majority of
394 lactococcal plasmids carry a highly related replicon. Microbiology 140, 1291-1300.

395 Sgorbati, B., Smiley, M.B., Sozzi, T., 1983. Plasmids and phages in *Bifidobacterium*
396 *longum*. Microbiologica 6, 169-173.

397 Shkoporov, A.N., Efimov, B.A., Khokhlova, E.V., Steele, J.L., Kafarskaia, L.I.,
398 Smeianov, V.V., 2008. Characterization of plasmids from human infant
399 *Bifidobacterium* strains: sequence analysis and construction of *E. coli*-
400 *Bifidobacterium* shuttle vectors. Plasmid 60, 136-148.

401 Siciliano, R.A., Mazzeo, M.F., 2012. Molecular mechanisms of probiotic action: a
402 proteomic perspective. Curr. Opin. Microbiol. doi: 10.1016/j.mib.2012.03.006.

403 Takata, T., Shirakawa, T., Kawasaki, Y., Kinoshita, S., Gotoh, A., Kano, Y., Kawabata,
404 M., 2006. Genetically engineered *Bifidobacterium animalis* expressing the
405 *Salmonella* flagellin gene for the mucosal immunization in a mouse model. J. Gene
406 Med. 8, 1341-1346.

407 Turrone, F., Foroni, E., Pizzetti, P., Giubellini, V., Ribbera, A., Merusi, P., Cagnasso, P.,
408 Bizzarri, B., de' Angelis, G. L., Shanahan, F., van Sinderen, D., Ventura, M., 2009.
409 Exploring the diversity of the bifidobacterial population in the human intestinal tract.
410 Appl. Environ. Microbiol. 75, 1534-1545.

411 Ventura, M., van Sinderen, D., Fitzgerald, G.F., Zink, R., 2004. Insights into the
412 taxonomy, genetics and physiology of bifidobacteria. Antonie van Leeuwenhoek 86,
413 205-223.

414 Ventura, M., Lee, J.H., Canchaya, C., Zink, R., Leahy, S., Moreno-Muñoz, J.A.,
415 O'Connell-Motherway, M., Higgins, D., Fitzgerald, G.F., O'Sullivan, D.J., van

416 Sinderen, D., 2005. Prophage-like elements in bifidobacteria: insights from
417 genomics, transcription, integration, distribution, and phylogenetic analysis. *Appl.*
418 *Environ. Microbiol.* 71, 8692-8705.

419 Xu, Y.F., Zhu, L.P., Hu, B., Fu, G.F., Zhang, H.Y., Wang, J.J., Xu, G.X., 2007. A new
420 expression plasmid in *Bifidobacterium longum* as a delivery system of endostatin for
421 cancer gene therapy. *Cancer Gene Ther* 14, 151-157.

422 Yazawa, K., Fujimori, M., Nakamura, T., Sasaki, T., Amano, J., Kano, Y., Taniguchi,
423 S., 2001. *Bifidobacterium longum* as a delivery system for gene therapy of
424 chemically induced rat mammary tumors. *Breast Cancer Res. Treat.* 66, 165-170.

518 **Table 1.-** Bacterial strains, plasmids and oligonucleotide primers utilized in this work.

519

Item	Genotype, phenotype or sequence	Source or reference
Strains		
<i>Escherichia coli</i> DH11S	<i>mcrA</i> , Δ (<i>mrr-hsdRMS-mcrBC</i>), Δ (<i>lac-proAB</i>), Δ (<i>rec1398</i>), <i>deoR</i> , <i>rpsL</i> , <i>srl-thi-F</i> ⁺ <i>proAB</i> ⁺ <i>lacIq</i> Δ M15	Invitrogen
<i>Bifidobacterium longum</i> M62	Human intestinal isolate harbouring three cryptic plasmids, including pSP02	Álvarez-Martín et al. (2007)
<i>B. longum</i> C63	Human intestinal isolate harbouring two cryptic plasmids	Álvarez-Martín et al. (2007)
<i>B. longum</i> C72	Human intestinal isolate harbouring three cryptic plasmids	Álvarez-Martín et al. (2007)
<i>B. longum</i> L25	Human isolate, plasmid free	IPLA Laboratory Collection
<i>Bifidobacterium adolescentis</i> LMG 10502	Human intestinal isolate, plasmid-free	BCCM/LMG ¹
<i>Bifidobacterium animalis</i> LMG 10508	Human intestinal isolate, plasmid-free	BCCM/LMG
<i>Bifidobacterium animalis</i> subsp. <i>lactis</i> Bb12	Isolated from a fermented milk starter	Chr. Hansen, Denmark
<i>Bifidobacterium breve</i> LMG 13208	Human intestinal isolate, plasmid-free	BCCM/LMG
<i>Bifidobacterium catenulatum</i> L48	Human intestinal strain containing pBC1	Álvarez-Martín et al. (2007)
<i>Bifidobacterium pseudocatenulatum</i> M115	Human intestinal isolate, plasmid-free	IPLA Laboratory Collection
<i>Bifidobacterium pseudolongum</i> LMG 11571	Human intestinal isolate, plasmid-free	BCCM/LMG
<i>Bifidobacterium thermophilus</i> LMG 11571	Human intestinal isolate, plasmid-free	BCCM/LMG
<i>Corynebacterium glutamicum</i> LMG 19741	Plasmid-free	BCCM/LMG
<i>Enterococcus faecalis</i> ATCC 47077	Plasmid-free	ATCC ²
<i>Lactobacillus casei</i> ATCC 393	Plasmid-free	ATCC
<i>Lactococcus lactis</i> subsp. <i>cremoris</i> MG 1363	NCDO 712 derivative, plasmid-free	Laboratory collection
Plasmids		
pUC18	Cloning vector, Ap ^r , 2.686 Kbp	Yanisch-Perron et al. (1985)
pUC19E	pUC-based cloning vector, Ap ^r Em ^r , 3665 bp	Laboratory collection
pAM4	<i>E. coli</i> - <i>Bifidobacterium</i> shuttle vector; Ap ^r Em ^r Tet ^r [tet(W)]	Álvarez-Martín et al. (2008)
pSP1	<i>E. coli</i> - <i>Bifidobacterium</i> shuttle vector; Ap ^r Em ^r , 6224 bp	This work
pSP2	<i>E. coli</i> - <i>Bifidobacterium</i> shuttle vector; Ap ^r Tet ^r , 7716 bp	This work
pSP3	<i>Bifidobacterium</i> vector, Em ^r , 3594	This work
Oligonucleotides		
	(5'-3')	
Bam1F	GATGATCGGATGGAGCCTG (315 bp apart from Bam1R)	This work
Bam1R	CGATTGGCGTCGTGATGG	This work
Bam2F	CACGGCTCACGTTGACAC (275 bp apart from Bam2R)	This work
Bam2R	GTCCATGCACCGCTCTATGC	This work
RepAF	ATGTCCGATGAGATCGTGAAG	This work
RepAR	CGCAGCACTCGGCCAGTC	This work
CopyF	CACGTTCGAAGAATTGAAG (101 bp apart from CopyR)	This work
CopyR	GATGATGTCTGCTCTTCG	This work
TufF	GGAGTACGACTTCAACCAG (110 bp apart from TufR)	This work
TufR	CATGTTCTTCACGAAGTCG	This work

520 Ap^r, Em^r, and Tet^r, resistance to ampicillin, erythromycin, and tetracycline, respectively.521 ¹BCCM/LMG, Belgium Coordinated Collection of Microorganisms/Laboratory for Microbiology, University of Gent, Belgium522 ²ATCC, American Type Culture Collection.

Table 2.- Host range and transformation frequency of pSP02-derived vectors.

Species and strain	Transformants ¹ per μg of DNA ² of the vector		
	pSP1	pSP2	pSP3
<i>B. adolescentis</i> LMG 10502	2.3×10^2	3.6×10^1	1.4×10^2
<i>B. animalis</i> subsp. <i>animalis</i> LMG 10508	7.4×10^1	5.0×10^0	5.8×10^1
<i>B. animalis</i> subsp. <i>lactis</i> Bb12	1.8×10^1	6.0×10^0	3.0×10^1
<i>B. breve</i> UCC 2003	3.5×10^3	8.2×10^2	4.2×10^3
<i>B. longum</i> L25	6.5×10^1	3.0×10^0	2.3×10^2
<i>B. pseudocatenulatum</i> M115	1.2×10^4	6.3×10^3	4.6×10^5
<i>B. pseudolongum</i> LMG 11571	4.2×10^1	4.1×10^1	3.6×10^1
<i>B. thermophilus</i> LMG 11571	1.9×10^1	2.2×10^1	8.0×10^0
<i>Corynebacterium glutamicum</i> LMG 19741	1.6×10^1	0	5.0×10^0
<i>Enterococcus faecalis</i> ATCC 47077	0	0	0
<i>Lactobacillus casei</i> ATCC 393	0	0	0
<i>Lactococcus lactis</i> subsp. <i>cremoris</i> MG 1363	0	0	0
<i>Escherichia coli</i> DH11S	6.2×10^6	6.8×10^6	0

¹Results are the mean of two independent transformations.

²The DNA of all constructs was isolated from *B. pseudocatenulatum* M115.

Figure 1




Figure 1




Figure 2

Figure 3




Figure 3




Figure 4

1 **FIGURE LEGENDS**

2

3 **Figure 1.-** Physical and genetic map of pSP02. The colored arrows indicate the direction
4 and approximate length of the identified ORFs. Direct repeats (DRs) and inverted repeats
5 (IRs) are indicated over the plasmid boundary by red- and blue-filled vertical blocks
6 respectively. DR-1/2 and DR-2/3 indicate overlapping pairs of direct repeats. The two AT-
7 rich regions are denoted by green-filled blocks. The position of the key restriction enzymes
8 *KpnI* and *BamHI* sites is also indicated.

9

10 **Figure 2.-** Detailed DNA sequence of the *ori* region of pSP02 and the initial part of its
11 corresponding *repA* gene, plus the latter's deduced amino acid sequence. Direct (DR) and
12 inverted (IR) repeats are indicated by converging and same-direction arrows respectively;
13 the numbering is as in Figure 2. The broken line indicates a copy of an imperfect DR6
14 repeat. The two AT-rich sequences are boxed.

15

16 **Figure 3.-** Diagram showing the construction of different pSP02-derived vectors. Ap^r, Em^r,
17 and Tet^r indicate the ampicillin, erythromycin and tetracycline resistance genes
18 respectively.

19

20 **Figure 4.-** Hybridization detection of ssDNA during the replication of pSP02 in
21 *Bifidobacterium longum* L25 using a digoxigenin labeled *repA* amplicon as a probe. Line 1,
22 purified, untreated DNA from whole-cell extracts; Line 2, DNA treated with nuclease S1.
23 M, molecular weight marker, digoxigenin-labeled lambda DNA digested with *EcoRI*.